310 related articles for article (PubMed ID: 28477742)
1. Drug resistance in pancreatic cancer: Impact of altered energy metabolism.
Grasso C; Jansen G; Giovannetti E
Crit Rev Oncol Hematol; 2017 Jun; 114():139-152. PubMed ID: 28477742
[TBL] [Abstract][Full Text] [Related]
2. Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy.
Amoedo ND; Obre E; Rossignol R
Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):674-685. PubMed ID: 28213330
[TBL] [Abstract][Full Text] [Related]
3. Molecular alterations contributing to pancreatic cancer chemoresistance.
Rajabpour A; Rajaei F; Teimoori-Toolabi L
Pancreatology; 2017; 17(2):310-320. PubMed ID: 28065383
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of pancreatic cancer: paving the way to better anticancer strategies.
Qin C; Yang G; Yang J; Ren B; Wang H; Chen G; Zhao F; You L; Wang W; Zhao Y
Mol Cancer; 2020 Mar; 19(1):50. PubMed ID: 32122374
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic ductal adenocarcinoma chemoresistance: From metabolism reprogramming to novel treatment.
Zhang J; Wang Y; Wang L; You L; Zhang T
Chin Med J (Engl); 2024 Feb; 137(4):408-420. PubMed ID: 37545027
[TBL] [Abstract][Full Text] [Related]
6. Microenvironment mediated alterations to metabolic pathways confer increased chemo-resistance in CD133+ tumor initiating cells.
Nomura A; Dauer P; Gupta V; McGinn O; Arora N; Majumdar K; Uhlrich C; Dalluge J; Dudeja V; Saluja A; Banerjee S
Oncotarget; 2016 Aug; 7(35):56324-56337. PubMed ID: 27472388
[TBL] [Abstract][Full Text] [Related]
7. Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters.
Dauer P; Nomura A; Saluja A; Banerjee S
Pancreatology; 2017; 17(1):7-12. PubMed ID: 28034553
[TBL] [Abstract][Full Text] [Related]
8. Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies.
Bahrami A; Khazaei M; Bagherieh F; Ghayour-Mobarhan M; Maftouh M; Hassanian SM; Avan A
J Cell Physiol; 2017 Nov; 232(11):2931-2937. PubMed ID: 28083912
[TBL] [Abstract][Full Text] [Related]
9. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
[TBL] [Abstract][Full Text] [Related]
10. A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer.
Coppola S; Carnevale I; Danen EHJ; Peters GJ; Schmidt T; Assaraf YG; Giovannetti E
Drug Resist Updat; 2017 Mar; 31():43-51. PubMed ID: 28867243
[TBL] [Abstract][Full Text] [Related]
11. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
12. Matrix control of pancreatic cancer: New insights into fibronectin signaling.
Topalovski M; Brekken RA
Cancer Lett; 2016 Oct; 381(1):252-8. PubMed ID: 26742464
[TBL] [Abstract][Full Text] [Related]
13. Design and discovery of novel quinazolinedione-based redox modulators as therapies for pancreatic cancer.
Pathania D; Sechi M; Palomba M; Sanna V; Berrettini F; Sias A; Taheri L; Neamati N
Biochim Biophys Acta; 2014 Jan; 1840(1):332-43. PubMed ID: 23954204
[TBL] [Abstract][Full Text] [Related]
14. Mitochondria and cancer chemoresistance.
Guerra F; Arbini AA; Moro L
Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):686-699. PubMed ID: 28161329
[TBL] [Abstract][Full Text] [Related]
15. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer.
Xiong G; Feng M; Yang G; Zheng S; Song X; Cao Z; You L; Zheng L; Hu Y; Zhang T; Zhao Y
Cancer Lett; 2017 Jul; 397():94-102. PubMed ID: 28254409
[TBL] [Abstract][Full Text] [Related]
16. Cancer-associated fibroblasts in pancreatic adenocarcinoma.
Pan B; Liao Q; Niu Z; Zhou L; Zhao Y
Future Oncol; 2015 Sep; 11(18):2603-10. PubMed ID: 26284509
[TBL] [Abstract][Full Text] [Related]
17. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.
Sahin IH; Iacobuzio-Donahue CA; O'Reilly EM
Expert Opin Ther Targets; 2016; 20(3):341-59. PubMed ID: 26439702
[TBL] [Abstract][Full Text] [Related]
18. MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells.
Sancho P; Burgos-Ramos E; Tavera A; Bou Kheir T; Jagust P; Schoenhals M; Barneda D; Sellers K; Campos-Olivas R; Graña O; Viera CR; Yuneva M; Sainz B; Heeschen C
Cell Metab; 2015 Oct; 22(4):590-605. PubMed ID: 26365176
[TBL] [Abstract][Full Text] [Related]
19. Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1beta and NO lead to inactivation of caspases.
Müerköster SS; Lust J; Arlt A; Häsler R; Witt M; Sebens T; Schreiber S; Fölsch UR; Schäfer H
Oncogene; 2006 Jun; 25(28):3973-81. PubMed ID: 16474845
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic Cancer Metabolism: Molecular Mechanisms and Clinical Applications.
Hosein AN; Beg MS
Curr Oncol Rep; 2018 May; 20(7):56. PubMed ID: 29752600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
